Browse diseases

…o identify clinical and socio-demographic correlates of PASS in systemic lupus erythematosus (SLE).Methods We analyzed data from the large multicenter RELES…

…phamide (Cyc) (A). Boxplots of methylation risk score (MRS) and Lupus Nephritis (LN) relapse in relation to LN induction treatment without Cycl…

…ng to sustained drug-free disease control in severe, refractory SLE. Phase 2 Breakfree-SLE trial ( NCT07015983) is currently enroll…

…Objectives Systemic lupus erythematosus (SLE) disease activity leads to irreversible organ damage, if n…

…ith males, females exhibited higher frequencies of arthritis in SLE, ACLE, DLE and chilblain LE (CHLE). In DLE, renal involvement, …

… pleura, may be observed in more than half of the patients with systemic lupus erythematosus (SLE). However, chylothorax, that is, accumulation of chyle in …

…uate the cost-effectiveness of telitacicept versus belimumab in SLE from the perspective of Chinese society.Methods The network met…

…ed DNA (anti-dsDNA) antibodies using a multiplex immunoassay in systemic lupus erythematosus (SLE), focusing on their association with organ-specific manife…

… damage prevention to optimise long-term HRQoL in patients with SLE.…

…ents.Conclusions MC is a useful therapy in mild–moderate active SLE. Using MC as the first drug after the failure of glucocorticoid…

…ed clinical manifestations and severity. Current tools like the SLE Disease Activity Index (SLEDAI) have limitations, including unv…

…resentation, risk factors and outcomes of PRES in patients with SLE remain insufficiently described.Methods We conducted a multicen…